Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

CAPS Rating: 3 out of 5

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Recs

0
Player Avatar latimerburned (92.85) Submitted: 12/26/2006 5:08:01 PM : Outperform Start Price: $37.44 VRTX Score: +74.38

Their Hep C drug has the potential to take this company to stardom, however, if the drug fails expect the company to crater. Still, this isn't a one trick pony as they also have tests going in RA, CF, HIV, cancer and pain. So, it's a diversified company that still has a lot riding on Hep C.

Featured Broker Partners


Advertisement